| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2024/05/15 | 22 : 29 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/05/11 | 06 : 27 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/03/09 | 06 : 49 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/03/02 | 06 : 40 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/03/01 | 21 : 35 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/03/01 | 10 : 23 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/03/01 | 06 : 44 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/29 | 22 : 09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/15 | 07 : 09 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/14 | 05 : 53 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/13 | 22 : 50 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/13 | 03 : 38 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/09 | 19 : 45 | PR Newswire (US) | Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/07 | 23 : 15 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/07 | 07 : 09 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/02/02 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/27 | 01 : 49 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/26 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/19 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/18 | 20 : 56 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/18 | 20 : 50 | GlobeNewswire Inc. | Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/16 | 21 : 00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/12 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/10 | 07 : 01 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/10 | 07 : 00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2024/01/05 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2023/12/23 | 09 : 00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2023/12/23 | 07 : 15 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2023/12/21 | 06 : 34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |
| 2023/12/18 | 19 : 45 | PR Newswire (US) | SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) | NASDAQ:EGRX | Eagle Pharmaceuticals Inc |